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ABSTRACT 
 
 Six insulin sensitive and six insensitive mares were used in a replicated 3 x 3 Latin square 
design to determine the pituitary hormonal responses (compared to vehicle) to sulpiride and 
thyrotropin-releasing hormone (TRH), two compounds commonly used to diagnose pituitary pars 
intermedia dysfunction (PPID) in horses. Mares were classified as insulin sensitive or insensitive 
by their previous glucose responses to direct injection of human recombinant insulin. Treatment 
days were February 25 and March 10 and 24, 2012. Treatments were sulpiride (racemic mixture, 
0.01 mg/kg BW), TRH (0.002 mg/kg BW), and vehicle (saline, 0.01 mL/kg BW) administered 
intravenously. Blood samples were collected via jugular catheters at -10, 0, 5, 10, 20, 30, 45, 60, 
90, 120 min relative to treatment injection. Plasma ACTH concentrations were variable and were 
not affected by treatment or insulin sensitivity category. Plasma melanocyte stimulating hormone 
(MSH) concentrations responded (P < 0.01) to both sulpiride and TRH injection, and were greater 
(P < 0.05) in insulin insensitive mares than in sensitive mares. Plasma prolactin concentrations 
responded (P < 0.01) to both sulpiride and TRH injection, and the response was greater (P < 0.05) 
for sulpiride; there was no effect of insulin sensitivity. Plasma thyroid stimulating hormone (TSH) 
concentrations responded (P < 0.01) to TRH injection only, and were higher (P < 0.05) in insulin 
sensitive mares in almost all time periods. Plasma LH and FSH concentrations varied with time (P 
< 0.05), particularly in the first week of the experiment, but were not affected by treatment or 
insulin sensitivity category. Plasma GH concentrations were affected (P < 0.05) only by day of 
treatment. The greater MSH responses to sulpiride and TRH in insulin insensitive mares were 
similar to, but not as exaggerated as, those observed by others for PPID horses. Also, the reduced 
TSH concentrations in insulin insensitive mares are consistent with the previous observation of 
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elevated plasma triiodothyronine concentrations in hyperleptinemic horses (later shown to be 
insulin insensitive as well). 
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INTRODUCTION1 
Exaggerated α-melanocyte stimulating hormone (MSH) and adrenocorticotropin (ACTH) 
responses to an injection of thyrotropin releasing hormone (TRH) have been suggested as 
possible indicators of pituitary pars intermedia dysfunction (PPID) in horses. (McFarlane et al., 
2006; Beech et al. 2007; Beech et al., 2011a,b). Similarly, the ACTH response to the dopamine 
antagonist, domperidone, was reported to be greater in horses affected with PPID than in normal 
horses (Sojka et al., 2006; Miller et al. 2008; Beech et al, 2011a). In addition to MSH and 
ACTH, TRH administration stimulates secretion of both thyroid-stimulating hormone (TSH) and 
prolactin (Thompson and Nett, 1984; Johnson, 1987; Johnson and Becker, 1987) in normal 
horses, and was reported to inhibit the secretagogue-induced secretion of growth hormone (GH) 
(Pruett et al., 2003). Domperidone, as well as sulpiride, another dopamine antagonist, also 
stimulates prolactin release in normal horses (Johnson and Becker, 1987; Brendemuehl and 
Cross, 2000; Kelley et al., 2006). 
Gentry et al. (2002) first described a hyperleptinemic condition in obese mares housed on 
pasture side-by-side with other obese mares with normal plasma leptin concentrations. Cartmill 
et al. (2003) reported that these hyperleptinemic mares were also hyperinsulinemic and had 
elevated plasma triiodothyronine concentrations, but did not have altered cortisol concentrations. 
Subsequently, Caltabilota et al. (2010) confirmed that the hyperleptinemic mares were in fact 
relatively insulin insensitive compared to normal mares of similar body condition. 
Approximately 60% of horses diagnosed with PPID have been found to have elevated blood 
insulin concentrations, indicative of insulin resistance, and elevated plasma ACTH-like activity  
____________________ 
1This Introduction, as well as Chapters II, III, and IV, are reprinted from Domestic Animal 
Endocrinology, volume 44, pages 204-212, with permission from Elsevier, Ltd. 
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is one of the currently accepted diagnostic tests indicative of PPID (McFarlane, 2011). However, 
like the hyperleptinemic mares described by Cartmill et al. (2003), horses with PPID do not 
necessarily have elevated cortisol concentrations or signs of adrenal hyperactivity (McFarlane, 
2011). 
Some horses presenting with symptoms of PPID seem to have alterations in cortisol 
concentrations that are not obvious or are too subtle to detect (Beech et al., 2007, 2011b; Haritou 
et al, 2008); however, reduced insulin sensitivity seems to be a common symptom of horses with 
equine metabolic syndrome (Johnson et al., 2012) and in PPID horses that also display excessive 
hair growth (Klinkhamer et al., 2011).  
The present experiment was conducted to determine whether the pituitary hormonal 
responses to sulpiride and TRH differed in normal mares relative to mares of known insulin 
insensitivity. The MSH and ACTH responses were monitored on the basis of their known 
responses in PPID horses. The remaining adenohypophyseal hormones were included 1) to 
confirm the biological activity of the injected compounds (e.g., prolactin and TSH after TRH 
administration) and 2) to assess any possible responsiveness not yet reported in the literature.  
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CHAPTER I 
REVIEW OF LITERATURE 
 
The Hypothalamic-Pituitary-Adrenal Axis  
The pituitary gland, also known as the hypophysis, is an endocrine organ comprised of two 
main parts, namely the adenohypophysis and the neurohypophysis, descending from two 
different embryological origins (Hadley and Livine, 2007). The adenohypophysis is comprised 
of endocrine cells originating from an inward invagination of the oral ectoderm of the primitive 
mouth cavity during development, known as Rathke’s pouch (Hadley and Levine, 2007. The 
neurohypophysis, made up of the pars nervosa and the infundibulum, is mainly a storage organ 
derived from the downward growth of the neural ectoderm and thereby mainly consisting of 
modified glial cells and axonal terminals of magocellular neurosecretory cells extending from the 
supraoptic and paraventricular nuclei in the hypothalamus (Hadley and Livine, 2007). These 
axons produce, store, and release oxytocin and arginine vasopressin into the capillary plexus in 
the pars nervosa (Berne and Levy, 2008).   
The adenohypophysis is anatomically subdivided into three sections: the pars tuberalis, pars 
distalis, and the pars intermedia. The pars tuberalis is a thin layer of endocrine tissue that 
surrounds the infundibular stalk or median eminence to provide an anatomical link between the 
pars distalis and the hypothalamus (Hadley and Livine, 2007). The pars distalis originates from 
the anterior wall of Rathke’s pouch and makes up the majority of the adenophypophysis (Hadley 
and Levine, 2007). It is made up of a collection of endocrine cells that synthesize and release 
hormones in response to hypothalamic releasing or inhibiting hormones (hypophysiotropins) 
(Hadley and Levine, 2007; McFarlane, 2011). These hormones reach the pars distalis by means 
of the median eminence, which connects the hypothalamus with the pars distalis through the 
hypophyseal portal system (HPS; Hadley and Levine, 2007).  
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shortly after formation (Hadley and Levine, 2007). However, in amphibians, reptiles, and most 
mammals, including the horse, the pars intermedia is well-defined (Hadley and Levine, 2007) 
 The hypothalamus is the basal part of the diencephalon, which lies below the thalamus. It 
is found in all vertebrate nervous systems and is responsible for coordinating hormonal and 
behavioral rhythms (Hadley and Levine, 2007). It includes the optic chiasm, the median 
eminence, the infundibulum, and the mammillary bodies (Hadley and Levine, 2007). The 
parvocellular neurons of the periventricular nucleus secrete the hypophysiotropins, 
gonadotropin-releasing hormone (GnRH), TRH, corticotropin-releasing hormone (CRH), 
somatostatin (SST), dopamine, and growth hormone-releasing hormone (GHRH) into the 
primary capillary bed (plexus) on the median eminence according to systemic feedback or 
external stimuli (Hadley and Levine, 2007). The portal vein then carries the peptides from the 
primary plexus to a secondary plexus within the adenohypophysis. There they can then regulate 
the secretion of hormones into the systemic circulation.  In contrast, the neurohypophysis is 
continuously connected with the media eminence via the infundibular stalk (Hadley and Levine, 
2007).  The main endocrine cells found in the pars distalis are the gonadotropes, somatotropes, 
thyrotropes, corticotropes, and lactotropes (Hadley and Levine, 2007; Berne and Levy, 2008). 
The hypothalamus exerts control of reproduction by secreting GnRH, which regulates the 
synthesis and secretion of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating 
hormone (FSH; Berne and Levi, 2008; McKinnon et al., 2011). In all species studied, including 
the horse, GnRH cells form a loosely connected groups scattered through the medial basal 
hypothalamus and called the GnRH pulse generator (Knobil, 1989). In horses, as in sheep, GnRH 
secretion is pulsatile, with pulse frequency varying with stage of cycle and season (McKinnon et 
al., 2011). Synthesis and secretion of GnRH are regulated by feedback from gonadal steroids 
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(Clarke and Pompolo, 2005). Neurotransmitters, such as noradrenaline, neuropeptide Y, 
dopamine, glutamate, and serotonin, can stimulate or inhibit GnRH neurons depending on the 
steroid milieu (McKinnon et al., 2011).  
The somatotropes are acidophilic cells that synthesize GH. They are either inhibited by 
SST or stimulated by GHRH or the gastro-enteric hormone, ghrelin (Berne and Levy, 2008). 
Other factors, such as stress, exercise (Thompson et al.,1992), nutrition, sleep, and even GH, can 
also affect GH synthesis (Hadley and Levine, 2007).  Growth hormone plays a major 
physiological role in growth and metabolism through direct and indirect pathways (Hadley and 
Levine, 2007). When secreted, GH stimulates the liver to produce insulin-like growth factor I 
(IGF-I; Hadley and Levine, 2007), which then affects growth through its action on skeletal, 
muscular, and other connective tissues (Hadley and Levine, 2007). Insulin-like growth factor-I 
can also negatively affect GH secretion though a long-loop feedback to the hypothalamus and 
induce SST secretion (Berne and Levy, 2008). 
Thyrotropin releasing hormone is a naturally occurring hypothalamic tripeptide that is the 
main regulator of TSH production and secretion, which in turn controls the release of thyroxine 
and triiodoththyronine in the thyroid (Hadley and Levine, 2007). Thyrotropin releasing hormone 
has also been shown to be an effective secretagogue of prolactin in many species (Hadley and 
Levine, 2007) as well as the horse (Thompson et al.,1984; Thompson et al., 1986; Johnson, 
1987; Johnson et al., 1987). It has been shown to stimulate the equine pituitary gland and release 
proopiomelanocortin (POMC)-derived peptides, including MSH release from the pars intermedia 
and ACTH in the pars distalis (McFarlane et al., 2006). In contrast, TRH inhibits GH secretion 
induced by GHRH (Pruett et al., 2003). This is like due to a direct effect on the somatropes to 
block GH release or via stimulation of somatostatin (Pruett et al., 2003).  
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Corticotropes in the pars distalis are stimulated by CRH produced in the neurons in the 
paraventricular nucleus in the hypothalamus (Schott, 2002). Corticotropin releasing hormone is 
released in a pulsatile pattern into the hypothalamic-hypophyseal portal circulation and increases 
in frequency in the early morning hours, thereby influencing ACTH to peak 2 to 4 hours before 
awakening (Schott, 2002). Adrenocorticotropin is released in response to CRH, which 
subsequently acts on the cells in the zona fasciculate of the adrenal cortex to induce synthesis 
and release of cortisol (Schott, 2002; Hadley and Levine, 2007). Cortisol release provides 
negative feedback to inhibit release of CRH from the hypothalamic neurons and ACTH from the 
corticotropes (Schott, 2002). Other glucocorticoids, such as corticosterone and dexamethasone (a 
synthetic glucocorticoid) can also exert negative feedback on ACTH secretion on the 
hypothalamic-pituitary level (Hadley and Levine, 2007). Adrenocorticotropin in the 
corticotropes is produced from posttranslational cleavage of  POMC by the enzyme prohormone 
convertase I into ACTH and β-lipotropin (Schott, 2002; McFarlane, 2011).  
Of the hormones found in the pars distalis of the adenohypothesis, synthesis of prolactin 
from the lactotropes is unique in that it is predominantly under dopaminergic inhibitory control 
by the hypothalamus (McKinnon et al., 2011). Dopamine is secreted into the primary plexus of 
the hypothalamic-hypophyseal portal system by the tuberoinfundibular (TIDA) neurons (Figure 
1; Lerant et al., 1996). Typically, prolactin secretion remains relatively constant with occacional 
surges occurring throughout the day (Roser et al., 1987; Thompson et al., 1994). Plasma 
concentrations of prolactin in most species is positively correlated with day length, with 
concentrations higher during the summer than in winter (Martinet et al., 1984; Johnson, 1987; 
Roser et al., 1987; Worthy et al., 1987). Exercise (Thompson et al., 1994), stress (Colborn et al., 
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Alpha-MSH was initially known for its role in controlling skin pigmentation in 
amphibians (Hadley, 1972). It has also shown to have potent anti-inflammatory actions by 
decreasing pro-inflammatory cytokines release in response to endotoxin administration in some 
species (Catania and Lipton, 1993) as well as playing an integral role in the leptin-melanocortin 
pathway, functioning in appetite-satiety balance and fat metabolism (Cone, 2005). 
 The pars intermedia is directly innervated by the periventricular hypothalamic 
dopaminergic neurons originating in the periventricular nucleus in the hypothalamus (Saland, 
2001). Regulatory signals can also be delivered by direct systemic arterial supply and from the 
hypothalamic-hypophyseal portal veins (McFarlane, 2006). Dopamine is secreted by the nerve 
terminals and binds to the dopamine D2 receptor (D2R) thereby inhibiting transcription of 
POMC and release of POMC-derived peptides (McFarlane, 2006) and prohormone convertase 
activity in mice (Saiardi and Borrelli, 1998). On the other hand, TRH has been shown to 
stimulate the pars intermedia via TRH receptors on the melanotropes (McFarlane et al., 2006; 
Beech et al., 2011a,b). 
Seasonality of Prolactin, MSH, and ACTH 
Serum concentrations of many metabolic hormones in the horse vary relative to season. For 
prolactin, serum concentrations are highest from June through August and lowest from 
November through February (Johnson, 1986). Johnson (1986) also determined that seasonal 
changes in concentrations of serum prolactin were directly correlated to both photoperiod and 
temperature, which parallels the loss (spring) and acquisition (autumn) of the winter hair coat 
(Kooistra and Ginther, 1975; Martinet et al., 1984; Thompson et al., 1997). Plasma 
concentrations of the melanocortins, including MSH and ACTH, have been shown to have a 
seasonal rhythm in the horse with concentrations peaking during the fall months (McFarlane et 
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al., 2004; Donaldson et al., 2005; Schreiber et al., 2012). Seasonal biorhythms of hormones are 
typically regulated by changes in photoperiod, mediated by nighttime production of melatonin 
from the pineal gland (McFarlane et al., 2011). It is possible that horses and ponies have a 
seasonal increase in POMC-derived peptides and a decrease in prolactin to metabolically prepare 
them for winter weather and a decrease in forage (McFarlane et al., 2004), but the mechanism 
that regulates the seasonal rhythm in the pars intermedia is still unknown.  
Apart from photoperiod, age has also been show to be an important factor in affecting 
seasonal secretion of POMC peptides. Schreiber et al. (2012) reported a moderate but significant 
positive correlation between age and endogenous ACTH concentrations, but minimal age 
influence, on MSH concentration. Latitude has been shown affect ACTH secretion in the 
autumn, with concentrations markedly higher in horses residing in Florida, modestly increased in 
horses in Massachusetts, and not increased in horses in Finland (McFarlane et al., 2011); MSH 
was apparently not affected by latitude (McFarlane et al., 2011).  
Insulin Resistance and Leptin 
Insulin resistance is defined as a condition in which normal concentrations of insulin 
produce a subnormal physiologic response (Kahn, 1978). In humans, it is caused by a failure of 
glucose uptake into muscle and adipose tissue by way of the insulin-sensitive glucose 
transporter-4 transport protein (Cline et al., 1999) Although the exact mechanism in horses is still 
unknown, horses develop a reduced sensitivity to insulin, which causes the pancreas to increase 
insulin production in order to maintain glucose homeostasis (Klinkhamer et al., 2011). Obesity in 
horses [as defined by Henneke et al. (1983) of having a body condition score of 7 or more] has 
been linked with insulin resistance (Frank et al., 2010). While not all insulin resistant horses are 
obese and not all obese horses are insulin resistant, obese horses are at most risk for developing 
  11
metabolic disorders and laminitis (Frank et al., 2006). In humans, obesity and lack of exercise 
are primary risk factors for insulin resistance, and the risk of developing type 2 diabetes 
increases with severity of obesity (Frank et al., 2006).  
 Leptin, a 16-kDa protein hormone secreted by white adipocytes, been found to play a 
regulatory role in insulin secretion by β cells of the pancreas and in insulin action and 
metabolism (Houseknecht et al., 1998). It has also been implicated in the regulation of food 
intake, energy expenditure, and energy balance in rodents and humans (Houseknecht et al., 
1998). Leptin acts in the hypothalamus to suppress appetite in normal individuals and thereby 
regulate the accumulation of adipose tissue in the body (Johnson, 2002). Leptin concentrations 
have been shown to vary directly with body mass index and percentage body fat in some species 
(Houseknecht et al., 1998; Prolo et al., 1998). This correlates with several studies that have 
determined an association between hyperleptinemia and insulin resistance in obese horses 
(Cartmill et al., 2003; Frank et al., 2006; Caltabilota et al., 2010). Cartmill et al. (2003, 2005) 
reported that hyperleptinemic horses had increased resting insulin concentrations. Since leptin 
can be directly stimulated by administration of insulin, while maintaining glucose within normal 
limits (Cartmill et al., 2003), Caltabilota et al. (2010) suggested that the hyperleptinemic 
condition is a result of reduced insulin insensitivity, which equates to long-term increases in 
insulin concentrations and hence a long-term stimulation of adipose tissue output of leptin.  
 Increases in leptin secretion have been observed in one study (Buff et al., 2002) to 
increase with age, with the greatest concentrations of leptin occurring in horses greater than 12 
years of age.   
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Equine Metabolic Syndrome  
Metabolic syndrome in humans, also referred to as “peripheral Cushing’s Syndrome”, 
insulin-resistance syndrome, and Syndrome X, is a collection of metabolic disorders, which 
include glucose intolerance, insulin resistance, central obesity, dyslipidemia, and hypertension 
(Eckel et al., 2005). When grouped together, they are associated with increased risk of coronary 
artery disease and type 2 diabetes (Eckel et al., 2005; Frank et al., 2010).  In 2002, Johnson first 
wrote the term equine metabolic syndrome (EMS) when he proposed that obesity, insulin 
resistance, and laminitis were all clinical signs of a syndrome recognized in horses and ponies. 
The term EMS was adopted to describe the condition in equids, as it bears similarities with the 
metabolic syndrome in humans (Eckel et al., 2005).  
 Equine metabolic syndrome affects horses that are characteristically obese and tend to be 
between the ages of 8 to 18 (Johnson, 2002). Established symptoms of EMS include increased 
regional or  general adiposity, insulin resistance characterized by hyperinsulinemia, and 
predisposition towards laminitis (Frank et al., 2010). Other factors that might be present are 
hypertriglyceridemia or dyslipidemia, hyperleptinemia, arterial hypertension, and loss of 
cyclicity in mares (Frank et al., 2010).  
Pituitary Pars Intermedia Dysfunction 
Pituitary pars intermedia dysfunction, formerly known as equine Cushing’s disease, is a 
progressive neurodegenerative disorder resulting from neurodegeneration of the dopaminergic 
periventricular neurons innervating the melanotropes of the pars intermedia (McFarlane et al., 
2005), that is characterized by hypertrophy and hyperplasia of the melanotropes resulting in an 
increased expression of POMC derived peptides (Dybdal et al., 1994; McFarlane et al., 2003). It 
is common in aged equids, and all breeds of horses and ponies can be affected (Schott, 2002). 
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Pars intermedia tissue from affected horses were reported to have an 8-fold decrease in dopamine 
concentration relative to tissue from age matched controls (Millington et al., 1988), and 
hypothalamic and pituitary tissues from horses with PPID were found to have a 6-fold reduction 
in levels of dopaminergic nerve terminals in the pars intermedia and 50% reduction levels of 
dopaminergic cell bodies in the periventricular nucleus (McFarlane et al., 2005). Similar 
histological findings were reported for D2R-deficient mice (Saiardi and Borrelli, 1998). Loss of 
D2R expression leads to increased POMC expression, hyperplasia of the pars distalis due to 
aberrant increase in prolactin levels from lactotropes, and hypertrophy of the pars intermedia 
(Saiardi and Borrelli, 1998). In these mice, the PCI activity increased 4 to 5-fold while the PCII 
activity increased only 2 to 3-fold (Saiardi and Borrelli, 1998). The relative difference in 
magnitude is thought to explain why horses with PPID produce pars intermedia-derived ACTH, 
as PCII activity cannot keep up with the relatively more abundant PCI activity (McFarlane, 
2011). 
 The increased expression of POMC derived peptides such as ACTH, MSH, β-endorphin, 
and CLIP is thought to lead to the clinical symptoms seen in PPID (McFarlane,  2011). The most 
unique and specific clinical sign associated with PPID is hirsutism, a delayed or incomplete coat 
shedding (McFarlane, 2011; McGowan et al., 2013). Other clinical signs include muscle atrophy, 
laminitis, polyuria/polydipsia, excessive sweating, susceptibility to infections, and lethargy or 
depression (Dybdal et al., 1994; Schott, 2002; McFarlane, 2011). 
The diagnosis of PPID is difficult, due to the slow progression of the disease. Currently 
available tests can yield false-negative results early in the course of the disease (Cordero et al., 
2012). Season also tends to confound tests if taken during autumn when ACTH and MSH levels 
are naturally elevated. Although horses with PPID maintain a seasonal regulation of the 
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hypothalamic-pituitary axis compared to normal horses, horses suspected of PPID have a more 
exaggerated seasonal hormone increase than normal horses (McFarlane et al., 2011). This 
suggests the seasonal hormonal rhythm is not regulated by dopamine, given that loss of 
functional dopaminergic neuronal input to the PI is expected (McFarlane et al., 2011).  
Rationale for Present Experiment 
Pituitary pars intermedia dysfunction is a very difficult disease to diagnose especially in its 
early stages. Several  experiments (McFarlane et al 2006; Beech et al., 2007, 2011) using TRH 
have been promising as an ambulatory method of differentiating PPID horses from regular 
horses, although season has to be taken into consideration when performing such tests 
(McFarlane et al., 2006; Beech et al., 2011). The use of oral domperidone administration to 
diagnose PPID proved not to be superior to TRH stimulation (Beech et al., 2011). The use of an 
injectable dopamine antagonist such as sulpiride to diagnose PPID has not been tested.  
As some horses age, they begin to lose their ability to regulate proper glucose levels, 
resulting often times in development of insulin resistance. Since insulin resistance appears to be 
present in 60% of horses with PPID (McFarlane, 2011), the current study focused on comparing 
various pituitary hormonal responses after administration of TRH, sulpiride, or vehicle in healthy 
and insulin resistant mares to see how these results compared to PPID horses reported by other 
researchers. As stated earlier in the Introduction (page 2), the remaining adenohypophyseal 
hormones were included 1) to confirm the biological activity of the injected compounds (e.g., 
prolactin and TSH after TRH administration) and 2) to assess any possible responsiveness not 
yet reported in the literature. 
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CHAPTER II 
MATERIALS AND METHODS 
 
Animals and Treatments 
 All procedures described herein were approved by the Institutional Animal Care and Use 
Committee of the LSU Agricultural Center. The mares used were of light horse breeds and were 
long-term residents of the Louisiana State University Agricultural Center horse farm in Baton 
Rouge, Louisiana. They were kept on native grass pasture most of the year and on winter 
ryegrass pasture when native grasses were dormant; grass hay was provided in transitional 
periods when grasses were insufficient to maintain body conditions. They remained on pasture 
except when experimental procedures were being performed. 
Twelve light horse mares were used that ranged in age from 6 to 21 yr, weighed between 
480 and 616 kg, and had body condition scores (Henneke et al., 1983) between 5 and 8. The 
mares were selected from the larger herd based on their relative insulin sensitivity, determined 
multiple times with consistent results, in previous experiments (Caltabilota et al., 2010; Earl et 
al., 2012). Six mares with low insulin sensitivity and six mares with normal sensitivity were then 
used in a replicated 3 x 3 Latin square design experiment to assess the hormonal responses to the 
two secretagogues reported to be useful in diagnosing PPID in horses (TRH and sulpiride 
(McFarlane et al., 2006; Sojka et al., 2006; Beech et al., 2007; Miller et al., 2008; Beech et al., 
2011a,b). 
Treatments in the experiment were as follows: 1) vehicle, 0.155 M NaCl in sterile water, 
0.01 mL/kg of body weight (BW), administered intravenously (i.v.), 2) TRH (obtained from 
Sigma Chem. Co., St. Louis, MO), 0.002 mg/kg BW in saline, administered i.v., and 3) sulpiride 
(from Sigma), 0.01 mg/kg BW of the racemic mixture in saline, administered i.v. Days of the 
experiment were February 25, 2012 and March 10 and 24, 2012. Treatments were predetermined 
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such that on each day of treatment, two mares of each insulin sensitivity category were 
administered each treatment.  
Mares were brought in from pasture the evening before each treatment day and were held 
in a dry lot with no feed or grass but free access to water. At approximately 07:00 the next 
morning, the mares were walked to an outdoor chute and were restrained to minimize contact 
with each other. Each mare then received a 14-gauge jugular catheter inserted on her left side 
that was held in place with cyanoacrylate glue. As long-term residents of the farm, the mares 
were routinely handled (moved into the lot, restrained, and catheterized) in this manner; thus, it 
posed no novel stimulation, and the mares displayed so signs of discomfort or anxiety. 
The mares were allowed to acclimate to the catheters and after approximately 1 hour, two 
samples of jugular blood were collected via the catheter (-10 and 0 samples) of each mare, and 
then the treatment for that day was injected through the catheter. Post-treatment blood samples 
were collected at 5, 10, 20, 30, 45, 60, 90, 120 min relative to time of treatment. In each case, the 
blood sample was split between two tubes for processing: one 7-mL tube containing 140 units 
sodium heparin (Sigma) and one 3-mL tube containing disodium EDTA as the anticoagulant 
(Sigma; 2 mg/mL of blood) and aproptinin (Sigma; 600 kallikrein inactivator units/mL of blood) 
as a protease inhibitor. All tubes with blood were placed on ice and were centrifuged within 15 
min at 1200 x g for 15 min. Plasmas were harvested from the two tubes and stored at -15°C. 
After all blood samples had been collected for that day, the mares were returned to pasture. 
In addition to the three treatment days, mares were also sampled between treatment days 
1 and 2 (March 3, 2012) to assess their 24-hour patterns of cortisol in plasma. For this sampling, 
the mares were kept in a dry lot that abutted the chute used on treatment days and were provided 
water and grass hay for ad libitum consumption. Blood samples (5 mL) were collected from the 
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left jugular vein by venipuncture (21-gauge needles) every 4 hours from 08:00 the first day until 
08:00 the next morning, for a total of 7 samples per horse. Mares were moved into the chute for 
each blood sampling and then returned to the dry-lot. Blood sampling was conducted under 
minimal lighting shielded from the mares' eyes. All blood samples from this procedure were 
placed in heparinized tubes and processed as described for the three treatment days. 
Radioimmunoassay Procedures 
The 10 samples of plasma for each mare on each treatment day were assessed for 
concentrations of LH (Thompson et al., 1983a), FSH (Thompson et al., 1983b), TSH (Thompson 
et al., 1984), prolactin (Colborn et al., 1991), and GH (Thompson et al., 1992) with previously 
validated radioimmunoassays developed in our laboratory. Commercially available reagents 
were used to measure concentrations of MSH (Euria α-MSH RIA, Immuno-Biological 
Laboratories, Minneapolis, MN) and ACTH (MP Biomedicals, Santa Ana, CA) in assays 
previously described by others (Karpac et al., 2008; Wade et al., 2010; Beech et al., 2011); only 
the 0-, 5-, 10-, 20-, and 30-min samples were assayed. Cortisol concentrations were also 
measured using commercially available reagents (Pantex, Santa Monica, CA) in duplicate 50-μL 
samples of plasma after extraction with 1.5 mL acetone; the extracts were air dried, reconstituted 
in assay buffer, and assayed directly. 
 To confirm the hyperleptinemic status of the mares in the two insulin categories, the -10 
blood sample for each horse and each week were assessed for plasma leptin concentration with a 
radioimmunoassay previously validated in our laboratory (Cartmill et al., 2003). Retrospectively, 
plasma concentrations of thyroxin and triiodothyronine were assessed in the same samples by 
radioimmunoassay with kits obtained commercially (MP Biomedicals).  
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Intra- and interassay coefficients of variation and limit of detection (concentration of 
hormone equivalent to the mean number of counts per minute of the assay zero standard tubes 
minus two standard deviations of those counts from the mean) for the assays averaged, 
respectively, 6%, 9%, and 0.2 ng/mL for LH; 7%, 11%, and 1.4 ng/mL for FSH; 5%, 8%, and 
0.02 ng/mL for TSH; 7%, 12%, and 0.2 ng/mL for prolactin; and 8%, 11%, and 0.5 ng/mL for 
GH. The cortisol, MSH, and ACTH samples were assayed in one batch each, and the intra-assay 
coefficient of variation and limit of detection were 6.0% and 0.1 μg/dL for cortisol, 5.5% and 1.2 
pmol/L for MSH, and 6.4% and 1.0 pg/mL for ACTH. The intra-assay coefficient of variation 
and limit of detection were 6.1% and 0.2 ng/mL for leptin, 2.7% and 1.0 μg/dL for thyroxin and 
2.3% and 8.0 ng/dL for triiodothyronine.  
Statistical Analyses 
Data for the hormonal responses over time after TRH, sulpiride, or vehicle injection were 
analyzed with SAS statistical software (SAS Institute, Cary, NC) by analysis of variance 
(ANOVA) that accounted for the repetitive nature of the sampling (repeated measures, Steel et 
al., 1997). Factors in the main analyses included insulin category, horse within category, 
treatment, category-treatment interaction, and day; these were tested with the mean square of the 
residual horse by category by treatment by day interaction term. The effects of time and the 
treatment by time and category by time interactions were tested with the residual error mean 
square. Data for leptin, thyroxin, triiodothyronine, and cortisol were analyzed in a repeated 
measure ANOVA with category tested by mare within category and time and the treatment by 
time interaction tested with residual error. For all analyses, differences between means were 
assessed by the least significant difference test (Steel et al., 1997). 
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Analysis of the LH and FSH data revealed that surges in one or both hormones occurred 
on several occasions in some mares. Although not preplanned, the frequency of these surges 
were analyzed by assigning a subjective intensity code (0 = no surge, 1 = small surge, and 2 = 
large surge) to all day by mare combinations. Small surges were considered as rapid increases in 
hormonal concentration of 0.5 to 2 ng/mL for LH and 5 to 20 ng/mL for FSH; corresponding 
large surges were >2 ng/mL and >20 ng/mL for LH and FSH, respectively. The effect of 
treatment, day of treatment, insulin sensitivity category, and the category-treatment interaction 
were analyzed with ANOVA and were tested with residual error. 
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CHAPTER III 
RESULTS 
 
The mean responses of plasma MSH concentrations to TRH, sulpiride, and vehicle 
injection are presented in Figure 3. A category by treatment by time interaction in the ANOVA 
(P < 0.0001) was observed for MSH concentrations, which did not change after vehicle injection, 
but increased  (P < 0.001) within 5 min after TRH or sulpiride injection. The greatest responses 
were after sulpiride injection, and the responses in insulin-insensitive mares were greater  (P < 
0.05) than in sensitive mares after both TRH and sulpiride injections. Mean areas under the 
response curves were greater in insensitive mares than in sensitive mares after both TRH (P = 
0.0013) and sulpiride (P = 0.0004) injection. 
Concentrations of ACTH (Figure 4) were variable and were not affected (P > 0.1) by 
category, treatment, time, or any interaction of these terms. Inspection of the data of individual 
mares indicated that one mare had an increase in ACTH concentrations from 1 to 600 pg/mL 
when treated with vehicle; most of the mares (n = 7) had no apparent changes after vehicle 
injection, whereas half (n = 6) the mares appeared to have responses after TRH or sulpiride.  
The responses of TSH to vehicle, TRH, and sulpiride injection are presented in Figure 5. 
A category by treatment by time interaction in the ANOVA (P = 0.0448) was observed for TSH 
concentrations, which did not change after injection of vehicle or sulpiride, but increased (P < 
0.05) within 20 min after TRH injection and remained elevated through 120 min after injection. 
Moreover, TSH concentrations were lower (P < 0.05) in insulin-insensitive mares compared to 
sensitive mares for most of the time periods during sampling except for 120 min after TRH 
injection and at 10, 20, 30, and 90 min relative to sulpiride injection. 
A treatment by time interaction was observed for prolactin concentrations (Figure 6) in 
the ANOVA (P < 0.0001), but no effect of insulin-sensitivity category. Prolactin concentrations 
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Figure 3. Mean plasma MSH concentrations (A, B, and C) and MSH areas under the response 
curves (D, E, and F) for insulin-sensitive vs insulin-insensitive mares after administration of 
vehicle, TRH, or sulpiride. *Differences (P < 0.05) between sensitive and insensitive mares for 
the time points marked; actual P values for the differences in areas between sensitive and 
insensitive mares are provided. Pooled SEM for plasma concentrations and areas were 4.9 
pmol/L and 3.6 pmol/mL x hour, respectively. MSH, a-melanocyte-stimulating hormone; TRH, 
thyrotropin-releasing hormone. 
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Figure 4. Mean plasma ACTH concentrations for insulin-sensitive vs insulin insensitive 
mares after administration of vehicle (A), TRH (B), or sulpiride (C). No difference (P > 0.1) was 
observed because of treatment or between sensitive and insensitive mares. Pooled SEM was 29 
pg/mL. TRH, thyrotropin-releasing hormone. 
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Figure 5. Mean plasma TSH concentrations for insulin-sensitive vs insulininsensitive mares after 
administration of vehicle (A), TRH (B), or sulpiride (C). An interaction (P = 0.045) was 
observed between insulin-sensitivity category and time after injection. Means in the 3 graphs 
differ (P < 0.05) between sensitive and insensitive mares for all time periods except for time 120 
after TRH and times 10, 20, 30, and 90 for sulpiride. Pooled SEM was 0.02 ng/mL. TRH, 
thyrotropin-releasing hormone; TSH, thyroid-stimulating hormone. 
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Figure 6. Mean plasma prolactin concentrations (A) and prolactin areas under the response 
curves (B) for all mares after administration of vehicle, TRH, or sulpiride. Insulin sensitivity 
category did not affect (P > 0.1) prolactin responses. Prolactin responses to sulpiride and TRH 
were both greater (P < 0.003) than that after vehicle injection (b or c vs a), and the sulpiride 
response was greater (P = 0.073) than that after TRH (b vs c). Pooled SEM for plasma 
concentrations and areas were 22 ng/mL and 37 ng/mL x hour respectively. TRH, thyrotropin-
releasing hormone. 
 
 
 
 
did not change after vehicle injection, but increased (P < 0.01) after TRH or sulpiride injection. 
Based on areas under the curve, the prolactin response to sulpiride was greater (P = 0.079) than 
the response to TRH. 
Concentrations of GH averaged 3.5 ng/mL in all samples (Figure 7), and were affected 
only by day in the ANOVA (P = 0.018). Means for the three treatment days, in chronological 
order, were 3.9, 3.6, and 3.1 ng/mL. Concentrations of LH and FSH (Figure 7) were affected by 
the time factor (minutes from injection) in the ANOVA (P < 0.002). Concentrations of FSH were  
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Figure 7.  Mean plasma concentrations of GH (A), LH (B), and FSH (C) for all mares after 
administration of vehicle, TRH, or sulpiride. Concentrations of GH were affected only by day of 
injection (P . 0.018), as were FSH concentrations (P . 0.0012). Concentrations of LH and FSH 
were affected by time relative to injection (P < 0.002). Pooled SEMs were 0.7, 0.5, and 12 
ng/mL for GH, LH and FSH concentrations, respectively. TRH, thyrotropin-releasing hormone.  
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also affected by day (P = 0.0012). The time effect was due primarily to increases that occurred 
on the first treatment day, on which several mares had surges in LH (n = 7) and FSH (n = 11) 
that occurred at some time after treatment injections (generally beginning at approximately 20 
min). On the second treatment day, 4 mares had surges in LH concentrations and 4 mares had 
surges in FSH concentrations. Oddly, no LH or FSH surges were observed on the third treatment 
day. The observed surges were not associated with treatment (P > 0.2). Analysis of the surge 
intensities in the post hoc analyses confirmed an effect of day of treatment (P = 0.0029 for LH 
and P < 0.0001 for FSH) but no effect of insulin sensitivity category or treatment. 
Concentrations of leptin, thyroxin, and triiodothyronine on treatment days 1, 2, and 3 are 
presented in Figure 8. Leptin concentrations were several-fold higher (P < 0.05) in insulin-
insensitive mares on treatment days 2 and 3 relative to sensitive mares. Insulin concentrations 
were higher (P > 0.001) in insulin-insensitive mares than in sensitive mares for all three days of 
treatment. Thyroxin concentrations were not affected  (P > 0.1) by insulin sensitivity category or 
day of treatment, whereas triiodothyronine concentrations were higher (P < 0.01) in insulin-
insensitive mares than in sensitive mares on the first day of treatment, but not on subsequent 
days. 
Cortisol concentrations in the samples collected every 4 hours over 24 hours are 
presented in Figure 9. Cortisol concentrations varied with time of day (P = 0.0002), being lowest 
in the afternoon and evening (15:00 through 23:00), but were not affected (P > 0.1) by insulin 
sensitivity category. 
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Figure 8. Mean plasma concentrations of leptin (A), insulin (B), thyroxin (C), and 
triiodothyronine (D) in insulin-sensitive and insulin-insensitive mares on the 3 days of treatment. 
Leptin (*P < 0.05), insulin (*P < 0.001), and triiodothyronine (*P < 0.01) concentrations differed 
between insulin sensitivity categories across days. Pooled SEMs were 2.6 ng/mL, 3.3 mIU/L, 0.5 
mg/dL, and 9.6 ng/dL for leptin, insulin, thyroxin, and triiodothyronine concentrations, 
respectively. 
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Figure 9. Mean plasma cortisol concentrations in insulin-sensitive and insulin-insensitive mares 
over 24 h of blood sampling on March 3, 2012. Cortisol concentrations varied throughout the 
day (P = 0.0002) but were not affected by insulin sensitivity category. Pooled SEM was 1.1 
mg/dL. 
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CHAPTER IV 
DISCUSSION 
 
Gentry et al. (2002) first described a hyperleptinemic condition in mares of good body 
condition (scores ranging from 5 to 7; Henneke et al., 1983) that persisted even after the body 
conditions were reduced by limited grazing. Cartmill et al. (2003) subsequently showed that the 
hyperleptinemic condition was accompanied by hyperinsulinemia and an exaggerated insulin 
response to glucose infusion, as well as a greater plasma concentration of triiiodothyronine. In 
2010, Caltabilota et al. confirmed that these hyperleptinemic mares were indeed insulin 
insensitive relative to mares with normal leptin concentration. The mares used herein had been 
consistently determined to be insulin sensitive or insensitive by the method of Caltabilota et al. 
(2010) in previous studies in our laboratory (Caltabilota et al., 2010; Earl et al., 2012; Lestelle, 
2012), and were chosen according to that history. The elevated plasma leptin concentrations in 
Figure 8 are thus consistent with our previous observations that hyperleptinemic mares are 
relatively insulin insensitive (i.e., insulin resistant). 
Sulpiride and TRH were selected for use as secretagogues in the present experiment 
according to their use in previous studies for the diagnosis of PPID. Several reports have 
confirmed that ACTH and MSH respond to TRH injection in horses (McFarlane et al., 2006; 
Beech et al. 2007; Beech et al., 2011a,b), and a few studies have confirmed an ACTH response 
to domperidone (Sojka et al., 2006; Miller et al., 2008; Beech et al., 2011a). Although no direct 
assessment of sulpiride has been reported for ACTH or MSH secretion, the known effect of 
domperidone and the fact that intermediate lobe dopamine receptors are of the D2 type 
(Munemura et al., 1980) in rats would indicate that these two hormones should respond to 
sulpiride as well. Not only did MSH concentrations increase after sulpiride injection in the 
present experiment, but the response was greater than the response to the standard TRH dose 
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used in previous trials (0.002 mg/kg, or 1 mg for a 500 kg horse). The dose of sulpiride used 
herein (0.01 mg/kg, or 5 mg of the racemic mixture for a 500 kg horse) was calculated to be 
approximately 50% of that dose producing maximal prolactin response in mares in March, as 
described by Clavier et al. (2012). For comparison, we have reported previously that the 
prolactin and TSH responses to TRH were similar for doses of 0.4, 2, and 10 mg (Thompson et 
al., 1984); thus the approximate 1-mg dose used herein could be considered saturating. Whether 
the MSH response to a saturating (maximal) dose of sulpiride differs from that to a saturating 
dose of TRH will have to be determined in future experiments. 
Although chosen for their low insulin sensitivity, the insensitive mares in the present 
experiment showed no overt signs normally ascribed to PPID (Schott, 2002; McFarlane, 2011). It 
is interesting, therefore, that these insulin-insensitive mares displayed a greater MSH response to 
TRH injection, similar to mares known to have PPID (McFarlane et al., 2006; Beech et al., 
2011a), as well as a greater MSH response to sulpiride. It should be noted that the difference in 
magnitude of the increase in MSH response between insulin-insensitive and sensitive mares 
(approximately 50 to 100%) in the present experiment is nothing near the 10-fold increase in 
response in mares confirmed with PPID (Beech et al., 2011a) relative to normal mares. 
Regardless, insulin insensitivity has been reported as a symptom of advanced PPID (Johnson et 
al., 2012), although more recent studies indicate a lesser (approximately 40%) prevalence in all 
diagnosed PPID cases (McGowan et al., 2013). Moore at al. (1979), was perhaps the first to 
describe symptoms in horses consistent with advanced PPID as a pituitary adenoma that resulted 
in hyperactivity of the adrenal gland. More recently, the peptide products of the hyperactive 
intermediate lobe themselves (ACTH, MSH, β-endorphin, etc.) have been indicated as the cause 
of some of the symptoms of PPID (McFarlane, 2011). Hyperadrenalism is typically associated 
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with hyperglycemia, hyperinsulinemia, and insulin resistance in various mammalian species 
(Hadley and Levine, 2007). In 1995, van der Kolk et al. reported that of twelve horses presented 
to the clinic with hirsutism and confirmed to have pituitary pars intermedia adenomas, 11 had 
elevated plasma insulin concentrations. One test that did not reliably predict PPID in the study of 
Dybdal et al. (1994) was diurnal cortisol patterns or levels. Similarly, Cordero et al. (2012) 
reported that normal mares often have blunted diurnal rhythms of cortisol, minimizing its 
usefulness for diagnosing PPID. Mean cortisol concentrations and cortisol diurnal rhythms in the 
insensitive mares in the present experiment were the same as those in sensitive mares. Thus, we 
would conclude that the underlying cause of their insulin insensitivity is not hyperadrenalism, 
unless the perturbation were so small as to be undetectable with normal cortisol assays. 
Unlike others (McFarlane et al., 2006; Beech et al. 2007; Beech et al., 2011a,b), we 
observed no significant changes in plasma ACTH concentrations in response to either sulpiride 
or TRH injection. As stated in Chapter III, approximately one-half of the mares, when their data 
were viewed individually, had apparent ACTH responses to one secretagogue or the other. More 
specifically, four mares had apparent responses to both sulpiride and TRH (but not saline), two 
mares had responses to sulpiride only, one mare had a response to TRH only, and two mares had 
large increases in ACTH after saline injection. Speculating that these latter two mares may have 
experienced some acute stressor to cause the rise in plasma ACTH, we examined the 
simultaneous concentrations of prolactin and GH, both of which respond to stressful situations 
within minutes in horses (Colborn et al., 1991; Thompson et al., 1992), but found little to no 
change in plasma concentrations associated with the surges of ACTH. Season has been shown to 
affect basal ACTH concentrations (McFarlane et al., 2011) as well as the ACTH response to 
TRH (Funk et al., 2011) in both normal horses and horses with PPID. The highest concentrations 
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occur in late summer and fall (Funk et al., 2011; McFarlane et al., 2011), and the lowest 
responses to TRH were found in February (Funk et al., 2011). Thus, season may partially 
account for the poor response of these mares to TRH and sulpiride in the present experiment 
(conducted in February and March). Age is another factor that correlates to plasma ACTH 
concentrations (Schreiber et al., 2012), particularly in the fall months. However, no apparent 
effect of age on the ACTH response to TRH or sulpiride was observed in this experiment.   
As stated earlier, the pituitary hormones other than MSH and ACTH were measured to 
confirm the biological activities of the injected sulpiride and TRH, from known effects reported 
previously, and to potentially detect any yet-to-be-determined effects on the other pituitary 
hormones. Although no new, unknown responses to sulpiride or TRH were observed, the 
expected effects on TSH and prolactin were in fact confirmed. Injection of TRH resulted in a 
somewhat gradual TSH response in all twelve mares, similar to the responses reported earlier by 
Thompson and Nett (1984). A novel observation was that TSH concentrations were consistently 
lower in insulin-insensitive mares relative to sensitive mares. Considering the known model for 
the hypothalamic-hypophyseal-thyroid axis (Hadley and Levine, 2007), these lower circulating 
TSH concentrations are likely because of elevated plasma triiodothyronine concentrations, as 
detected in the first week of the present experiment, and also reported by Cartmill et al. (2003) 
for hyperleptinemic mares and geldings. If this were the case, it could be that the constantly 
elevated insulin concentrations occurring in insulin-insensitive horses in some way affect the 
thyroid gland to secrete more triiodothyronine than normal or affect the peripheral conversion of 
thyroxin to triiodothyronine. Such an effect would be analogous to the hyperinsulinemic effect 
on leptin concentrations, causing hyperleptinemia in horses (Cartmill et al., 2005). 
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The prolactin responses to sulpiride and TRH were as expected, from previous reports 
(Johnson, 1987; Johnson and Becker, 1987; Kelley et al., 2006), and were produced consistently 
by the two secretagogues. Although prolactin concentrations produced after injection differed in 
their timing of increase (rapid after sulpiride and more slowly after TRH), areas under the 
response curves were not different when calculated over the entire 2-hour blood sampling period. 
Spurious increases in prolactin secretion have been reported (Roser et al., 1987; Thompson et al., 
1992; Funk et al., 2011), and occurred occasionally in the present experiment after vehicle 
injection. However, the relative increase in prolactin concentrations after such occurrences were 
small (e.g., 3 to 5 ng/mL) compared to the responses to sulpiride and TRH and had little 
influence on the overall mean of the twelve mares. 
Secretion of GH in horses, as in many species, is episodic (Thompson et al., 1992), with 
increases in plasma GH occurring every few hours. The episodes of GH secretion in the present 
experiment were minimal, as seen by the relatively constant mean GH concentrations in Figure 
7. The significant variation of GH concentrations because of day of the experiment (3.9 ng/mL 
on the first day, dropping to 3.1 ng/mL on the last day) did not seem to have any physiological 
relevance. 
Spurious increases in plasma concentrations of LH and FSH were observed in the present 
experiment, but the cause of these increases is unknown. As stated in Chapter III, most of these 
spurious increases occurred approximately 20 min or more after injection, and most occurred on 
the first day of treatments, with none occurring on the last day of treatments. Thompson et al. 
(1983c, 1984) reported surges in plasma LH and FSH concentrations in response to insertion of 
intravaginal sponges in mares in winter, and later reported episodes of secretion in seasonally 
anovulatory mares not touched other than for blood sampling through a jugular catheter 
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(Thompson et al., 1987). Retrospective measurement of progesterone in the first sample on each 
treatment day in the present experiment, coupled with the average concentration of LH for that 
day, indicated that 8 of the 12 mares were still seasonally anovulatory (low LH and no 
progesterone) on the first day of treatments (February 25), and 5 mares remained that way 
through March 24, the last treatment day. The majority of surges in LH (64%) and FSH (73%) 
across all mares occurred on days when both LH and progesterone were low (i.e., likely 
anovulatory), which is consistent with our previous observations (Thompson et al., 1983c; 
Thompson et al., 1984). 
In conclusion, insulin-insensitive mares displayed an exaggerated MSH response to both 
TRH injection and sulpiride injection relative to sensitive mares. Insulin-insensitive mares also 
had reduced plasma TSH concentrations and higher insulin, leptin and triiodothyronine 
concentrations in general. In contrast, mean cortisol concentrations and the pattern of cortisol 
over a 24-hour period were similar in both groups. Although the differences in MSH 
characteristics were analogous to those observed with PPID, their magnitude was relatively 
small. Possible cause-effect relations that involve hyperleptinemia, hyperinsulinemia, elevated 
triiodothyronine concentrations, and elevated MSH responses to secretagogues are not obvious 
from the current literature and deserve further study in horses.  
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SUMMARY AND CONCLUSIONS 
 
In this experiment, insulin-insensitive and sensitive mares were administered TRH or 
sulpiride, a dopamine antagonist, to evaluate the response of the pars distalis and pars intermedia 
hormones. Cortisol was monitored as well, although several reports show horses with PPID do 
not necessarily have elevated cortisol concentrations or signs of adrenal hyperactivity 
(McFarlane, 2011; Cordero et al., 2012).  
Results showed no significant difference in plasma ACTH concentration to TRH or 
sulpiride in both insulin-insensitive and sensitive mares. In contrast, insulin-insensitive mares 
had a significant MSH response to TRH, similar to mares known to have PPID (McFarlane et al., 
2006; Beech et al., 2011a), and an even greater response to sulpiride, although not near the 
magnitude seen in PPID (Beech et al., 2011a). Prolactin responses to TRH and sulpiride were as 
expected from previous reports (Johnson and Becker, 1987; Johnson, 1987; Kelley et al., 2006) 
and there were no noticeable changes in thyroxine, triiodothyronine, GH, LH, and FSH. Plasma 
insulin and leptin were higher in insulin-insensitive mare with levels rising as mares transitioned 
from winter into spring. Mean cortisol concentration and cortisol diurnal rhythm were the same 
in both groups.  
In conclusion, insulin-insensitive mares were easily distinguishable from sensitive mares 
from their increased MSH response to TRH and even greater response to sulpiride, which 
parallels the characteristics observed for PPID horses, though to a lesser extent. Sulpiride could 
potentially be effective in diagnosing PPID, and research using sulpiride to distinguish between 
PPID horses and normal horses is warranted. The relationship between insulin insensitivity and 
MSH secretion in response to TRH or sulpiride also deserves further investigation.  
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